News
-
Oseltamivir beats supportive care for patients hospitalized with seasonal influenza
Investigator Anthony Bai, MD, MSc, and infectious disease expert Christina Thornton, MD, PhD, discuss a large analysis that showed an in-hospital mortality rate of 3.5% for oseltamivir vs 4.9% for supportive care.
-
ORCA-3 replicates strong tobacco cessation results for cytisinicline
The ORCA-3 trial demonstrated that cytisinicline, a reformulated compound, significantly outperformed placebo by nearly six times in helping adults who smoke to quit.
-
Study shows earlier vasopressin initiation for sepsis reduced in-hospital mortality
Critical care expert Natalie Achamallah, MD, FCCP, said OVISS data support guidelines that recommend earlier vasopressin as well as lower norepinephrine doses.
-
EHR data confirm effectiveness of RSV vaccine in adults aged 60 and older
Pauline Terebuh, MD, MPH, said the results aligned with previous trials; however, Shaun J. Grannis, MD, said more data are needed to determine the durability of the protection.
-
UK trial finds propofol remains preferred ICU sedation agent
The recent A2B trial found that neither dexmedetomidine nor clonidine are superior to propofol and may increase risks of agitation and bradycardia.
-
As-needed albuterol-budesonide found to benefit mild asthma
Study author Craig LaForce, MD, and pulmonologist Kevin Fussell, MD, discuss findings from the BATURA trial and their clinical implications.
-
Probiotics shortened fever duration in children with upper respiratory tract infections
Investigator Carlo Agostoni, MD, said the data show probiotic use was associated with a median reduction of fever by two days compared with placebo.
-
COURSE trial shows importance of biomarker testing in COPD
While overall the trial was negative, Meilan King Han, MD, MS, and Sanjay Ramakrishnan, MBBS, PhD, said it demonstrated the promise of tezepelumab for patients with baseline blood eosinophil counts ≥ 150 cells/µL.
-
Procalcitonin levels may guide antibiotic duration in patients with suspected sepsis
Paul Dark, MD, PhD, said a 10% reduction in duration of antibiotic use shown in a recent study may seem small, but in the context of antibiotic stewardship, a 10% reduction is important.
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Fernando Martinez, MD, FCCP, said he expects the treatment options for fibrotic lung disease will soon become more complex—in a good way—as more effective therapies become available.
